Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/1b study of AB928 in combination with AB122 or chemotherapy in patients with Non-small cell lung cancer and renal cell carcinoma

Next Previous
X
Search
Trial Profile

Phase 1/1b study of AB928 in combination with AB122 or chemotherapy in patients with Non-small cell lung cancer and renal cell carcinoma

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etrumadenant (Primary) ; Zimberelimab (Primary)
  • Indications Non-small cell lung cancer; Renal cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 11 Jun 2018 According to the Arcus Biosciences media release, the IND application for this trial will be submitted this month.
    • 16 May 2018 New trial record
    • 09 May 2018 According to the Arcus Biosciences media release, company initiated the submission of regulatory filings for this trial and data from the dose-escalation portion of this trial will be presented in the first half of 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top